Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.
Yang J, Hong W, Shi H, He C, Lei H, Zhou Y, Yang H, Alu A, Chen Z, Yang Y, Yu W, Tang C, Wang J, Li B, Huang Q, Li J, Yang L, Wang W, Shen G, Yang J, Zhao Z, Song X, Su Z, Wei Y, Sun Q, Lu S, Wang Z, Wang Y, Lu G, Li W, Wei X.
Yang J, et al. Among authors: zhao z.
Nat Commun. 2024 Dec 30;15(1):10778. doi: 10.1038/s41467-024-55087-z.
Nat Commun. 2024.
PMID: 39738039
Clinical Trial.